Epsilon Therapeutics partners with scientists in regions endemic for parasitic worm diseases to discover novel, non-toxic therapeutics for chronic inflammatory diseases. Up to 40% of Americans suffer from some form of chronic inflammation, including allergy, inflammatory bowel disease, and type 2 diabetes. Natural mechanisms, such as those mediated by parasitic worms, may be the key to developing highly effective and non-toxic therapeutics.